Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
The soon available AmoyDx® FGFR1-4 NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in the FGFR1-4 genes on DNA and RNA from FFPE material. The panel covers the complete coding sequence of the four genes. As recommended in various publications (e.g. Lamarca, A. et al., 2023), the detection of FGFR gene fusions is carried out at the RNA level; unknown fusion partners can also be identified. The library is prepared using the hybrid capture method (ddCAP technology) with an optimized DNA/cDNA co-library preparation workflow, which mostly takes place in a single reaction tube.
As with all AmoyDx® NGS panels, the sequence data is analyzed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
For further information, please contact us at molpath@zytomed-systems.de
1. Lamarca, A. et al. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma ESMO Open, Volume 8, Issue 6, 102049, 2023
We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
Today, we are proud to announce that ZytoVision, our sister company, received the IVDR certification!